Acute meyloid leukemia
Conditions
Interventions
control group:Venetoclax and azacitidine
Sponsors
Second Affiliated Hospital, Army Medical University
Eligibility
Sex/Gender
All
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. The patient fully understands this study and voluntarily participates and signs an Informed Consent Form (ICF); 2. Patients diagnosed with adult acute myeloid leukemia; Elderly patients aged 60 to 90 years (including threshold); No gender limitation; 3. ECOG score = 3 points; or KPS score =90 points; or PS score =1 points; 4. The expected survival period is>3 months; 5.No radiotherapy, chemotherapy, targeted therapy, hematopoietic stem cell transplantation, or any other treatment should be received within 4 weeks prior to enrollment.
Exclusion criteria
Exclusion criteria: 1. Under 60 years old who can accept standard dose or intensive chemotherapy; 2. Individuals with severe heart disease or abnormal lung function that affects survival; 3. Merge active second tumor; 4. Can not come back for eximination on time; 5. Unsuitable subjects for this study determined by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of MRD negativity;complete remission(CR); | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective Response Rate (ORR);1 years overall survival;1 year Progression-Free-Survival(PFS);Recurrence rate;Severe adverse reaction;mortality rate; | — |
Countries
China
Contacts
Public ContactWen Qin
Second Affiliated Hospital, Army Medical University
Outcome results
None listed